Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

347.94 -5.34 (-1.51%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

64 65 Next >

Got $5,000? These 3 Nasdaq Stocks Are Dirt Cheap Buys Right Now ↗

April 03, 2025

Via The Motley Fool

P/E Ratio Insights for Amgen ↗

April 02, 2025

Via Benzinga

Amgen Options Trading: A Deep Dive into Market Sentiment ↗

April 01, 2025

Via Benzinga

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? ↗

March 31, 2025

The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.

Via Investor's Business Daily

2 Surefire Dividend Stocks That Could Pay You for Life ↗

March 28, 2025

Via The Motley Fool

Amgen's Options: A Look at What the Big Money is Thinking ↗

March 12, 2025

Via Benzinga

Assessing Amgen: Insights From 9 Financial Analysts ↗

March 05, 2025

Via Benzinga

Behind the Scenes of Amgen's Latest Options Trends ↗

March 04, 2025

Via Benzinga

2 Large-Cap Stocks with Solid Fundamentals and 1 to Turn Down

March 28, 2025

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

Via StockStory

Which Dow Jones Stock Is Cheaper, Amgen or Merck? ↗

March 28, 2025

Via The Motley Fool

Topics Intellectual Property Stocks

Is the Market Bullish or Bearish on Amgen? ↗

March 26, 2025

Via Benzinga

Why Pharma and Biotech Stocks Got Thrashed on Tuesday ↗

March 25, 2025

Via The Motley Fool

Amgen Options Trading: A Deep Dive into Market Sentiment ↗

March 25, 2025

Via Benzinga

Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen ↗

March 22, 2025

Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

March 21, 2025

Via Benzinga

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

March 21, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its...

Via StockStory

Topics Artificial Intelligence

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress ↗

March 20, 2025

Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.

Via Benzinga

Behind the Scenes of Amgen's Latest Options Trends ↗

March 20, 2025

Via Benzinga

Prediction: These 2 Stocks Will Outperform the Market Through 2030 ↗

March 18, 2025

Via The Motley Fool

Motley Fool Market Cap Showdown: Bill Barker vs. Emily Flippen ↗

March 14, 2025

Via The Motley Fool

Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year ↗

March 13, 2025

Amgen's Uplizna met key endpoints in a Phase 3 gMG trial, showing sustained efficacy and improvement in muscle function with two doses a year.

Via Benzinga

Is Eli Lilly Stock a Buy? ↗

March 11, 2025

Via The Motley Fool

Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study ↗

March 10, 2025

Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies.

Via Benzinga

3 Magnificent Growth Stocks to Buy in March ↗

March 08, 2025

Via The Motley Fool

2 Dividend Stocks to Buy for a Lifetime of Passive Income ↗

March 07, 2025

Via The Motley Fool

2 Reasons to Watch AMGN and 1 to Stay Cautious

March 06, 2025

Since September 2024, Amgen has been in a holding pattern, posting a small loss of 1.8% while floating around $314.91. The stock also fell short of the S&P 500’s 7% gain during that period.

Via StockStory

Topics Stocks

Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials ↗

March 06, 2025

Via Benzinga

AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

March 05, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis ↗

March 03, 2025

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

64 65 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.